PharVision Advisers’s Evolent Health EVH Stock Holding History

PharVision Advisers’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-44,967	Closed	-$180K	–	281
2025 Q4	$180K	Buy	44,967 +29,330	+188%	+$163K	0.09%	590
2025 Q3	$132K	Buy	+15,637	New	+$152K	0.07%	590

Other funds holding EVH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Rubicon Founders Nashville, Tennessee $138M AUM 61.96% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PharVision Advisers's EVH Position: Q1 2026 in Review

PharVision Advisers sold out of Evolent Health (EVH) in Q1 2026, closing a stake of 44,967 shares — an estimated $180K sold.

PharVision Advisers first reported a position in EVH in Q3 2025 and held it in 2 quarters. The position peaked at $180K in Q4 2025. 191 funds tracked by Wall St. Rank hold EVH as of Q1 2026.

PharVision Advisers reported no remaining Evolent Health position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 44,967 Evolent Health shares in Q1 2026, an estimated $180K.
PharVision Advisers first reported a position in Evolent Health in Q3 2025 and held it in 2 quarters.
PharVision Advisers's Evolent Health position peaked at $180K in Q4 2025.
191 funds tracked by Wall St. Rank held Evolent Health as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.